Jack Shuang Hou: Novo Nordisk to Present New Haemophilia Data on Investigational Denecimig at ISTH 2026
Jack Shuang Hou, Diagnostic Executive, Microfluidics and Immunoassay Specialist, shared a post on LinkedIn:
“Novo Nordisk to Present New Haemophilia Data at ISTH 2026 Highlighting Investigational Denecimig (Mim8)
Novo Nordisk will present new clinical and real-world data across its haemophilia portfolio at the ISTH 2026 Congress, featuring multiple analyses of investigational denecimig (Mim8) and new pediatric data for Alhemo (concizumab).
The presentations reinforce Novo Nordisk’s long-standing commitment to advancing innovation in rare bleeding disorders.
1.Denecimig (Mim8) Highlights
Phase 3 FRONTIER4 long-term data
- Adults, adolescents and children
- Patients with or without FVIII inhibitors
- Once-monthly, every-2-week and weekly prophylaxis evaluated
- Long-term efficacy, safety and patient-reported outcomes
2.Alhemo (Concizumab)
First Phase 3 explorer10 pediatric data
- Children younger than 11 years with haemophilia A or B and inhibitors
- Efficacy, safety and PK and PD results
- Pediatric indication remains investigational
3.Looking Ahead
Novo Nordisk will also present real-world evidence, physician preference studies and mechanistic research while continuing regulatory review of denecimig, following its U.S. BLA submission in 2025.
Leadership Perspective
Martin Holst Lange, Chief Scientific Officer at Novo Nordisk, said the company’s research reflects decades of listening to the haemophilia community while advancing person-centered innovation to improve care.
My takeaway
Novo Nordisk continues to build one of the industry’s most comprehensive haemophilia portfolios. With flexible prophylactic dosing, expanding pediatric evidence, and next-generation bispecific antibodies like denecimig, the company is positioning itself to further reshape long-term management across the full spectrum of haemophilia A.”
Stay updated with Hemostasis Today.
-
Jun 28, 2026, 19:05Pinar Demirtepe: Not All “Blood Thinners” Are the Same
-
Jun 28, 2026, 19:05Andrea Cesari: Comparing Catheter-Based Reperfusion Strategies for Intermediate-High-Risk PE
-
Jun 28, 2026, 19:02Nassim Emteir: Interpreting TSAT with Ferritin to Guide Iron Deficiency Diagnosis and Treatment
-
Jun 28, 2026, 19:00Andrew Jackson: Predicting PICC-Related Venous Thrombosis in Patients Undergoing Radiotherapy
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
-
Jun 28, 2026, 09:41Sung-mok Jung: How Environmental Drivers Influence SFTS Occurrence